IL17A and osteoporosis: Further efforts will be required to elucidate the crucial mechanism of IL-17 in the recipient BMMSC-based pathology of secondary osteoporosis in SLE, which may lead to novel recipient BMMSC-targeting therapeutics for skeletal disorders.